§ 522.1698 Pentazocine lactate injection.

(b) Sponsor. See No. 053501 in §510.600(c) of this chapter.

(c) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions of use were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

(d) Conditions of use—(1) Amount. Dogs and cats—10,000 units per pound of body weight once daily. Horses—3,000 units per pound of body weight once daily.

(2) Indications for use. Treatment of infections of dogs, cats, and horses caused by penicillin-susceptible organisms such as Streptococci, Staphylococci, and Corynebacteria.

(3) Limitations. Not for use in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37333, Aug. 18, 1992]

§ 522.1704 Sodium pentobarbital injection.

(a)(1) Specifications. Sodium pentobarbital injection is sterile and contains in each milliliter 64.8 milligrams of sodium pentobarbital.

(2) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is indicated for use as a general anesthetic in dogs and cats. Although it may be used as a general surgical anesthetic for horses, it is usually given at a lower dose to cause sedation and hypnosis and may be supplemented with a local anesthetic. It may also be used in dogs for the symptomatic treatment of strychnine poisoning.

(ii) The drug is administered intravenously “to effect”. For general surgical anesthesia, the usual dose is 11 to 13 milligrams per pound of body weight. For sedation, the usual dose is approximately 2 milligrams per pound of body weight. For relieving convulsive seizures in dogs, when caused by strychnine, the injection should be administered intravenously “to effect”. The drug may be given intraperitoneally if desired. However, the results of such injections are less uniform. When given intraperitoneally, it is administered at the same dosage level as for intravenous administration. The dose must be reduced for animals showing under-nourishment, toxemia, shock and similar conditions.

(iii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b) [Reserved]


§ 522.1720 Phenylbutazone injection.

(a) Specifications. The drug contains 100 or 200 milligrams of phenylbutazone in each milliliter of sterile aqueous solution.

(b) Sponsors. (1) Approval for use of the 200 milligrams per milliliter drug
in dogs and horses: See sponsor Nos. 000061, 000856, 000859, and 061623 in §510.600(c) of this chapter.

(2) Approval for use of the 200 milligrams per milliliter drug for use in horses: See sponsor Nos. 000010 and 058005 in §510.600(c) of this chapter.

(3) Approval for use of the 100 milligrams per milliliter drug in dogs and horses: See sponsor No. 000856 in §510.600(c) of this chapter.

(c) Conditions of use for dogs. (1) It is used for the relief of inflammatory conditions associated with the musculoskeletal system.

(2) It is administered intravenously at a dosage level of 10 milligrams per pound of body weight daily in 3 divided doses, not to exceed 800 milligrams daily regardless of weight. Limit intravenous administration to 2 successive days. Oral medication may follow.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use for horses. (1) It is used for the relief of inflammatory conditions associated with the musculoskeletal system.

(2) It is administered intravenously at a dosage level of 1 to 2 grams per 1,000 pounds of body weight daily in 3 divided doses, not to exceed 4 grams daily. Limit intravenous administration to not more than 5 successive days.

(3) Not for use in animals intended for food.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§ 522.1850 Polysulfated glycosaminoglycan.

(a) Specifications. (1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.

(2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.

(b) Sponsor. See No. 010797 in §510.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Horses—(i) Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

(ii) Amount—(A) Intra-articular use (carpal): 250 mg once a week for 5 weeks.

(B) Intramuscular use (carpal and hock): 500 mg every 4 days for 28 days.

(iii) Limitations. Do not use in horses intended for human consumption.

(2) Dogs—(i) Indications for use. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

(ii) Amount. 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).